

INDEPENDENT CRO OVERSIGHT FOR EARLY-STAGE BIOTECHS



Biotech Advisory Lab

PROTECT YOUR RUNWAY. STRUCTURE YOUR OUTSOURCING.
MAKE INFORMED CRO DECISIONS.

Why Independent Advisory Matters

Transitioning into clinical development is not only an operational milestone — it is a strategic and financial inflection point. Decisions around CRO selection, governance, and budgeting will directly impact:

- Cash burn trajectory
- Execution quality and timelines
- Investor confidence
- Long-term scalability

Without structured oversight, outsourcing can become a hidden financial and operational risk.

What Makes Biotech Advisory Lab Different

- Fully independent – zero vendor bias
- Dual perspective: Clinical Operations + Financial Structuring
- Governance-driven CRO engagement model
- Designed specifically for early-stage biotech constraints

Our Advisory Model

LEVEL 1	LEVEL 2	LEVEL 3	LEVEL 4
Clinical Readiness Assessment: Structured evaluation of outsourcing preparedness	Clinical Transition Structuring: Governance framework and operational alignment	Budget & Vendor Evaluation: Independent benchmarking and financial validation	Ongoing Strategic Oversight: CRO governance and performance alignment

Typical Challenges We Address

- High cash burn without structured oversight
- Weak governance during CRO execution
- Misaligned budgets and unrealistic RFP responses
- Financial exposure embedded in outsourcing contracts

Key Stakeholders

- Early-Stage Biotechs
- Venture Capital & Life Sciences Investors
- Biotech Incubators & Accelerators
- Strategic Advisory Partners

Start with an independent CRO Readiness assessment

Aurelio del Pino
Founder

apino@biotechadvisorylab.com
+34 611 771 660

www.biotechadvisorylab.com

